NanoPro – a Framework for Probiotically-Guided Nanovector Therapy
Preprint
Abstract
The “antigen problem”, i.e. the disconnect between the broad spectrum of therapeutic modes enabled by the range of viral and synthetic nanoparticles for which workable receptor-targeting architectures exist and the relative dearth of addressable target receptors on most tumors, is a long-standing challenge in targeted tumor nanotherapy. Here we provide in vitro -proof-of-principle for NanoPro, a platform for guiding nanoscale therapeutics to otherwise antigenically indistinct tumors via probiotically-released tumor cell-binding tags, ProTags. These consist of an orthogonal antigen (GFP or ALFA) fused to the heparin-binding domain of placenta growth factor-2 and serve as attachment receptors for ProTag-targeted nanovectors. ProTag release from Escherichia coli Nissle 1917 was facilitated by deletion of the membrane-tethering lpp gene, which increased ProTag supernatant concentrations 16.5–fold compared to the parental strain without impacting viability. HBD-dependent decoration with ProTag in bacterial supernatant followed by treatment with receptor-targeted aGFP- or aALFA-lentiviral vectors resulted in majority transduction of MC-38 and MDA-MB-468 tumor cell lines with antigen specificities of 96.5% and 98.5%, respectively, depending on the choice of nanobody. This ProTag-mediated interaction was notably robust, with selective transduction still observed at 625–fold supernatant dilution, warranting further exploration of the utility of the NanoPro system for tumor-restricted delivery of nanotherapeutics.Keywords
Funding Information
- NIH (R01EB030352)
- NIH (R01CA313939)
This publication has 32 references indexed in Scilit:
- Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platformsMolecular Therapy, 2022
- Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917ACS Synthetic Biology, 2020
- The ALFA-tag is a highly versatile tool for nanobody-based bioscience applicationsNature Communications, 2019
- Translation Initiation is Controlled by RNA Folding Kinetics via a Ribosome Drafting MechanismJournal of the American Chemical Society, 2016
- Modulation of protein properties in living cells using nanobodiesNature Structural & Molecular Biology, 2009
- Automated design of synthetic ribosome binding sites to control protein expressionNature Biotechnology, 2009
- Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectorsNature Protocols, 2009
- Extracellular recombinant protein production from an Escherichia coli lpp deletion mutantBiotechnology and Bioengineering, 2008
- lpp deletion as a permeabilization methodBiotechnology and Bioengineering, 2007
- Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine StrainNature Biotechnology, 1988